FDA Draft Guidance for Medical Devices Intended for Weight Loss
FDA has released a draft guidance entitled Medical Devices with Indications Associated with Weight Loss - Premarket Considerations outlining recommendations for companies developing devices intended to support weight management or weight loss, and detailing the types of information manufacturers should include in premarket submissions.
The guidance applies to several categories of devices, including ingested space-occupying devices and endoscopic suturing systems that alter gastric anatomy to promote weight loss. These devices fall under classification regulations such as 21 CFR 876.5982 for ingested, transient space-occupying devices and 21 CFR 876.5983 for endoscopic suturing devices.
According to the agency, the document is intended to help manufacturers prepare submissions under multiple regulatory pathways, including the De Novo classification process, PMA process, and the 510(k) clearance program. While the recommendations are nonbinding, the agency said they are designed to help sponsors meet applicable regulatory requirements and demonstrate a device’s safety and effectiveness.
The draft guidance lays out detailed expectations for device descriptions, labeling, sterility, biocompatibility, and other technical considerations. Manufacturers are advised to provide comprehensive device descriptions, including engineering schematics or diagrams explaining how components work together, as well as explanations of the scientific principles underlying device function. Submissions should also describe design specifications, materials used, and performance characteristics. For devices containing nitinol, the FDA recommends including additional information consistent with existing agency guidance on evaluating medical devices that incorporate the nickel-titanium alloy.
The agency also outlines labeling expectations for devices marketed for weight-loss indications. Submissions should include proposed labels and instructions describing the device’s intended use, directions for use, and relevant warnings. For prescription devices, labeling should provide sufficient information for healthcare professionals to use the device safely, including indications, contraindications, hazards, side effects, and precautions.
The guidance recommends that manufacturers include summaries of clinical studies supporting the device, covering key elements such as study design, number of participants, investigational sites, primary and secondary endpoints, and results. FDA says information on changes in obesity-related conditions — such as type 2 diabetes or hypertension — may help describe the device’s overall benefit-risk profile.
FDA highlighted potential risks associated with some weight-loss devices, particularly liquid-filled intragastric balloons. In labeling for these devices, manufacturers should disclose safety concerns identified in previous FDA communications, including risks such as spontaneous hyperinflation, acute pancreatitis, esophageal or gastric perforation, aspiration, and death.
Additionally, the guidance describes recommendations for sterility and microbial control. Devices labeled as sterile should include detailed descriptions of sterilization methods and validation data. For devices provided non-sterile — such as those that only contact the gastrointestinal tract without breaching tissue — FDA recommends manufacturers describe microbial monitoring procedures and provide testing data to ensure bioburden levels remain safe. Other sections of the guidance address pyrogenicity testing to prevent fever-inducing reactions, packaging and shelf-life validation to ensure device integrity over time, and biocompatibility assessments for patient-contacting materials.